DURING CHRONIC LIVER INJURY, hepatic stellate cells (HSCs) undergo a process of activation from a quiescent "storing" to a highly proliferative "myofibroblast-like" phenotype. Besides a fibrogenic response, this activation process also leads to the acquisition of enhanced contractile properties. Both factors have been implied in the increased intrahepatic vascular resistance (IHVR) to portal flow, but especially the recognition that hypercontractile HSCs participate in the increased intrahepatic vascular tone provides the rationale for targeting these cells in the treatment of portal hypertension in advanced chronic liver disease (5, 12, 23) . Due to the expression of smooth muscle proteins and the strategical anatomical location around hepatic sinusoids, a resemblance to pericytes or vascular smooth muscle cells has been proposed, leading to the assumption of a "smooth muscle-like" contraction pattern (12, (22) (23) (24) . Yet, this supposed smooth muscle-like contraction pattern of activated HSCs conflicts with the alleged transition to a myofibroblastlike activated HSC phenotype. In smooth muscle cells, contraction is mainly powered by a Ca 2ϩ -dependent myosin activation. Increased intracellular Ca 2ϩ levels, either via inositol trisphosphate (IP 3 ) or Ca 2ϩ influx through L-type channels, give rise to the activation of Ca 2ϩ /calmodulin-dependent myosin light chain kinase (MLCK), which, in turn, results in increased phosphorylation of the regulatory light chain of myosin (rMLC). Phosphorylation of rMLC allows myosin ATPase to be activated by actin, leading to actomyosin crossbridging and cell contraction (21, 28) . In nonmuscle cells, including activated HSCs, increased phosphorylation of rMLC has also been correlated with increased contractility (11, 26) . However, in contrast to smooth muscle cells, several studies (10, 19, 27) favor non-Ca 2ϩ -dependent contraction pathways to be the key event in force generation by myofibroblasts, of which the RhoA signaling and PKC-dependent pathway are the most relevant. Both these latter pathways inhibit the phosphatase activity of myosin light chain phosphatase (MLCP), leading to a delayed degradation of phosphorylated rMLC and thus promoting contraction (21, 27) .
Since the contributions of these different pathways have not yet been fully elucidated for HSC contraction, we therefore aimed to 1) define the relative role of Ca 2ϩ -dependent and -independent pathways in the actomyosin interaction of HSCs ( Fig. 1) , using a three-dimensional stress-relaxed collagen lattice contraction model; 2) compare the degree of Ca 2ϩ dependency of vascular smooth muscle cells (VSMCs), cardiac myofibroblasts, and activated HSCs; and 3) determine the relevance of these in vitro findings in the increased IHVR associated with thioacetamide (TAA)-induced cirrhosis in the rat.
MATERIALS AND METHODS

Cell Isolation and Culture
HSCs were isolated from male Wistar rats, weighing 300 -400 g (Animal House, Leuven, Belgium), as approved by the local Ethical Committee on Animal Research and as described previously (3) . In brief, following in situ perfusion of the liver with collagenase type IV (Sigma, St. Louis, MO) and pronase E (Merck, Darmstadt, Germany), the resulting cell suspension was fractionated by density gradient centrifugation using Optiprep (Nycomed). Cells were harvested at densities of Ͻ1.053 (9% Optiprep) according to Alpini et al. (1) . Viability and purity was systematically Ͼ95%, as determined by trypan blue exclusion and morphological characterization. Cells were seeded on uncoated plastic culture dishes and cultured in William's E medium supplemented with 10% FCS, 0.6 IU/ml insulin, 2 mM glutamine, and 1% antibiotic-antimycotic solution (Invitrogen, Merelbeke, Belgium). The medium was renewed every 48 -72 h. Characterization of rat liver-derived myofibroblast-like cultures, established by culturing enriched HSC fractions on plastic, was performed by staining with anti-␣-smooth muscle actin (␣-SMA), anti-desmin, and anti-synaptophysin, as previously described (3, 4) . Experiments were performed between the first and third passages (1:3 split ratio) using three cell cultures from independent isolations. Rat cardiac ventricular myofibroblasts (a gift from Dr. V. Petrov, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium) and rat aortic VSMCs (a gift from Prof. Dr. S. Janssen, Center for Transgene Technology and Gene Therapy, University of Leuven, Leuven, Belgium) were isolated and cultivated as previously described (9, 20) .
Three-Dimensional Stress-Relaxed Collagen Lattice Contraction Model
The ability of HSCs to contract three-dimensional collagen matrixes was assessed as previously described with some slight modifications (29) . In brief, hydrated collagen gels were prepared using rat tail tendon collagen I (Becton Dickinson Labware, Becton Dickson, Bedford, MA) and adjusted to physiological strength and pH with 1 N NaOH and 10ϫ PBS at 4°C. Afterward, the collagen solution was mixed with a HSC suspension so that the final solution resulted in a collagen concentration of 1.5 mg/ml and 250,000 cells/ml. A 500-l aliquot of the collagen solution was then cast into each well of a 24-well tissue culture plate (Falcon, Meylan, France) and, after 1 h, was covered with complete culture medium (1 ml/well) to ascertain adequate gelation. Afterward, the polymerized collagen matrix containing HSCs remained attached to the culture dish for 24 h, leading to mechanical loading ("stressed") (16) . After 24 h, stabilized lattices were washed twice with 1ϫ PBS, followed by the addition of 1 ml serum-free culture medium/well containing 1 Ci 3 H2O (Amersham Biosciences, Roosendaal, The Netherlands). Depending on the experiment, presumed agonists and/or inhibitors were added. To initiate matrix contraction, mechanically stressed matrixes were released by gentle circumferential dislodgement of the lattice using a micropipette tip ("relaxation"). Cell-mediated contraction was measured by determining the relative partioning of 3 H2O between the gel phase and surrounding medium following 24 h of contraction, thereby allowing the estimation of gel phase volumes. More specifically, the separate tritium activities of the medium and gel phase were measured in 10 ml oscillation fluid (Perkin-Elmer) using a Beckmann liquid scintillation spectrometer. Control cell-free gels provided estimates for the precontraction volume and allowed us to determine relative changes in volume (percent contraction). All data presented here are from experiments using at least three sets of three collagen lattices using culture-activated HSCs from three different rat HSC isolations.
The same setup was used in the experiments comparing contractions of VSMCs, HSCs, and cardiac myofibroblasts. In these specific experiments, the extent of contraction was expressed relative to FCS-induced contraction to allow comparisons between cell types.
Inhibitors and Agonists Affecting Contractility
Depending on the experiment, FCS (10%), the ␣ 1-adrenergic agonist methoxamine (10 Ϫ4 M, Sigma), or the Ca 2ϩ ionophore A-23187 (Sigma) were used as agonists. Mostly, FCS was used because its ease of use, high availability, and ability to elicit as powerful a contraction as endothelin-1 (25) . The actomyosin interaction, the end target of both Ca 2ϩ -dependent and Ca 2ϩ -independent pathways, was studied with the use of 2,3-butanedione 2-monoxime (BDM), a nonmuscle myosin ATPase inhibitor (Sigma). The following kinase inhibitors were used: the calmodulin-mediated MLCK inhibitor W-7 (Sigma), the Rho kinase inhibitor Y-27632 (Calbiochem, La Jolla, CA), and the PKC inhibitor staurosporin (Sigma). Kinase inhibitors and BDM were added to agonist-free collagen lattices 5 min prior to the addition of an agonist and release. To evaluate the effect of increased intracellular Ca 2ϩ on contraction in the different cell types, the Ca 2ϩ ionophore A-23187 was used under agonist-free conditions. To investigate the effect of inhibition of MLCP, calyculin (Calbiochem) was added to Ca 2ϩ -depleted and normal (Ca 2ϩ containing) lattices. The former lattices were obtained by washing lattices with 1ϫ Ca 2ϩ -free PBS (3 ϫ 2 min each), followed by 1ϫ Ca 2ϩ -free PBS ϩ 3 mM EGTA (2 ϫ 5 min each and then 14 min) and a final set of washes with 1ϫ Ca 2ϩ -free PBS ϩ 3 mM EGTA ϩ 0.01 M A-23187 (3 ϫ 2 min each). The final washing step allowed depletion of intracellular Ca 2ϩ . 
Western Blot Analysis for rMLC and Phosphorylated rMLC
HSCs, cultured for 24 h in the presence of W-7, Y-27632, staurosporine, or FCS alone, were harvested and homogenized in lysis buffer (0.125 M Tris ⅐ HCl, 4% SDS, 20% glycerol, 0.02% bromophenol blue, and 0.2 M DTT). After heat denaturation (100°C for 5 min) and centrifugation (13,000 g for 10 min), equal amounts of protein (6.5 g) were run on a 7% SDS-PAGE gel and then transferred onto a nitrocellulose Protran membrane (Schleicher & Schuell, Dassel, Germany). Membranes were blocked with 5% blocking solution (milk powder) in 1ϫ PBS for 1.5 h at room temperature to avoid nonspecific binding. Thereafter, blots were incubated overnight with primary antibodies against rMLC and phosphorylated rMLC (1:200, Santa Cruz Biotechnology, Santa Cruz, CA). The next day, membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (SwaR-HRP, 1:500, Prosan, Merelbeke, Belgium), and immunoreactivity was visualized using chemiluminescence detection (ECL-plus, Amersham Biosciences). Membranes were stained with Ponceau staining to confirm equal protein loading and transfer between lanes. Densitometric quantification of Western blot signal intensity was performed with Un-Scan-IT Gel software (Silk Scientific) and calculated as percentages to mean values of HSCs treated only with FCS.
Fluo-4 Visualization of Intracellular Ca 2ϩ
HSCs, grown on glass coverslips, were incubated with 5 M fluo-4 ϩ 0.025% pleurionic acid (Molecular Probes) under FCS-free conditions. Coverslips were subsequently transferred to the coverglass chamber of a confocal scanning microscope (Nikon TE 300, Noran Oz). Cells were observed and photographed before, during, and after the addition of FCS-free medium containing 0.01 M A-23187.
Animal Model of Cirrhosis
Male Wistar rats, weighing 200 -250 g, were intoxicated with TAA in drinking water. The TAA concentration was adapted weekly to changes in body weight, leading to homogenous macronodular cirrhosis with all the typical characteristics of portal hypertension after 18 wk, as previously described (13, 14) .
In Situ Liver Perfusion
In TAA-treated cirrhotic and control rats (n ϭ 25 each), the effect of the ␣ 1-agonist methoxamine was studied on IHVR with and without preincubation with W-7, Y-27632, and staurosporin by in situ liver perfusion, as previously described (13, 14) . Briefly, the portal vein was cannulated and perfused through a 14-gauge angiocath with oxygenated Krebs solution at 37°C. After the inferior vena cava was transsected, allowing the perfusate to escape, a thoracotomy was performed to cannulate the suprahepatic inferior vena cava. Once the effluent was clear, recirculation was set up with a volume of 150 ml of buffer at a constant flow of 35 ml/min. Perfusion pressure was continuously monitored (Dataq, Akron, OH). Criteria of liver viability included the gross appearance of the liver, stable perfusion pressure (starting value Ϯ 1 mmHg), and stable buffer pH (7.4 Ϯ 0.1) during the initial 30-min stabilization period.
Statistical Analysis
Statistical analysis was performed using SigmaStat 2.0 (Jandel, San Rafael, CA). An unpaired Student's t-test, Mann-Whitney rank-sum test, or ANOVA was used when appropriate. Data are given as means Ϯ SE. P Յ 0.05 was considered statistically significant.
RESULTS
In the first part of the experiments, HSC contraction was investigated in vitro with the use of the stress-relaxed collagen lattice contraction model. In the second part, in vitro findings were corroborated with in vivo experiments in the in situ perfused rat liver. imaging, which showed a maximal rise in intracellular Ca 2ϩ within seconds (Fig. 2) . A dose-response curve with A-23187 showed maximal contraction of 54.7 Ϯ 1.8% at 0.01 M. Since this amounts to only 75.6 Ϯ 1.8% of FCS-promoted contraction, increasing intracellular Ca 2ϩ appears insufficient to exclusively cause contraction (Figs. 3 and 4) . The equivalent maximal contraction relative to FCS-induced contraction generated in VSMCs and cardiac myofibroblasts amounted to 85.1 Ϯ 2.3% and 34.6 Ϯ 2.1%, respectively (P Ͻ 0.001 vs. the equivalent effect in HSCs; Fig. 4) .
In Vitro Results
Relevance of intracellular
MLCK, the downstream effector of the Ca 2ϩ -dependent pathway, was inhibited using W-7, an inhibitor of calmodulinmediated activation of MLCK. In FCS-promoted HSC contraction, this resulted in an attenuation to 17.6 Ϯ 2% at 10 Ϫ4 M (vs. 77.4 Ϯ 1.2% for control, P Ͻ 0.001; Fig. 5 ).
When the effect of W-7 (10 Ϫ4 M) was evaluated on maximal Ca 
Relevance of Ca
2ϩ -independent pathways in HSC-mediated gel contraction. First, MLCP, the supposed converging end point of Ca 2ϩ -independent pathways, was inhibited using calyculin, a type 1 phosphatase inhibitor. Calyculin (10 Ϫ9 M) was able to induce contraction of HSC-embedded collagen lattices in the absence of FCS (53.7% vs. 15.3% under FCSfree conditions, P Ͻ 0.05). To further specify the relative role of MLCP activity in HSC-mediated contraction, HSC contraction was examined under Ca 2ϩ -depleted and Ca 2ϩ -containing conditions in the presence or absence of calyculin (10 Ϫ9 M). Under similar Ca 2ϩ -depleted conditions, contraction occurred more efficient when MLCP was inhibited (4 Ϯ 2.3% vs. 30 Ϯ 2.7%, P ϭ 0.002; Fig. 6 ). In Ca 2ϩ -containing lattices, a comparable effect was observed when MLCP was inhibited (15.3 Ϯ 3.8% vs. 53.7 Ϯ 5.2%, P ϭ 0.004), but the degree of contraction was increased compared with Ca 2ϩ -depleted conditions. These data not only illustrate an auxiliary role for MLCP in the regulation of HSC contraction in addition to increasing levels of intracellular Ca 2ϩ but also document its involvement in the phenomenon of "Ca 2ϩ sensitization." Subsequently, known inactivating upstream signaling pathways of MLCP, more specifically, Rho-associated kinase and PKC-mediated pathways, were evaluated. Y-27632 and staurosporin, their respective inhibitors, dose dependently attenuated FCS-promoted HSC contraction (Fig. 7, A and B) . In contrast, Y-27632 (10 Ϫ4 M) and staurosporin (25 nM), which both inhibited FCS-promoted contraction by Ͼ85%, inhibited calyculin-promoted contraction by maximally 35% and 27%, respectively, strengthening the hypothesis that MLCP is their downstream target (Fig. 7C) . Furthermore, W-7 (10 Ϫ4 M), an inhibitor of calmodulin-mediated activation of MLCK, did not change calyculin-promoted contraction at all, suggesting its unimportance in the regulation of MLCP (Fig. 7C) .
Relevance of actomyosin interaction in HSC-mediated contraction. To assess whether the end point of Ca 2ϩ -dependent and -independent pathways was indeed an actomyosin interaction, BDM, a nonmuscle myosin II-Ca 2ϩ -ATPase inhibitor, was added to the culture medium prior to release. This led to a dose-dependent decrease in FCS-promoted contraction, indicating the requirement of an actomyosin interaction in the contraction of stress-relaxed HSC-embedded collagen matrixes (Fig. 8A) . To further substantiate the involvement of the calmodulin/MLCK-, Rho kinase-, and PKC-mediated pathways in this actomyosin interaction, we additionally examined the phoshorylation of MLC by Western blot analysis. Densitometric analysis of MLC and phosphorylated MLC (Fig. 8B) showed constitutive expression of MLC under all conditions. The addition of W-7 (10 Ϫ4 M), Y-27632 (10 Ϫ4 M), and staurosporin (25 nM) decreased the amount of phosphorylation of MLC compared with control conditions (FCS) (P Ͻ 0.001 vs. the degree of phosphorylation under control conditions).
Relevance of Ca 2ϩ -dependent and -independent pathways in the presence of the ␣ 1 -adrenergic agonist methoxamine. To finally refute the possibility that these pathways were relevant exclusively to FCS stimulation, we repeated the experiments with W-7, Y-27632, and staurosporin in the presence of the ␣ 1 -adrenergic agonist methoxamine, for which activated HSCs express the receptors and biosynthetic enzymes (18) . Except for under basal conditions comparing only both agonists, we observed no differences to FCS-induced contraction in the presence of W-7, Y-27632, and staurosporin (Fig. 9) .
Results in In Situ Perfused Normal and Cirrhotic Rat Livers
In agonist-free conditions, basal IHVR of cirrhotic rat livers was already increased compared with normal rat livers (0.22 Ϯ 0.01 vs. 0.13 Ϯ 0.01 mmHg⅐min⅐ml Ϫ1 , respectively, P Ͻ 0.001). The addition of methoxamine (10 Ϫ4 M) led to an increase in IHVR in both cirrhotic and normal perfused rat livers (0.65 Ϯ 0.02 vs. 0.32 Ϯ 0.02 mmHg⅐min⅐ml Ϫ1 , respectively, P Ͻ 0.001). In the cirrhotic perfused rat liver, the response to methoxamine was aggravated compared with the normal perfused rat liver (change in increase in IHVR: 0.39 Ϯ 0.03 mmHg⅐min⅐ml Ϫ1 for TAA vs. 0.21 Ϯ 0.02 mmHg⅐min⅐ml Ϫ1 for control, P ϭ 0.001), which is consistent with the phenomenon of "hyperresponsiveness" to vasocon- -independent pathways in the increased active IHVR associated with cirrhosis ( Fig. 10 ). In the normal liver, we noted a reduction in IHVR only after inhibition of Ca 2ϩ -independent pathways and to a lesser extent than that found in cirrhosis: Ϫ43.1 Ϯ 4.2% (P ϭ 0.008 vs. TAA ϩ Y-27632) and Ϫ40.2 Ϯ 4.2% (P ϭ 0.038 vs. TAA ϩ staurosporin) (Fig. 10) .
DISCUSSION
Accumulating evidence indicates that the contractile force generated by activated HSCs not only drives scar contraction in cirrhosis but also modulates the hepatic microcirculation (12, 19, (22) (23) (24) 26) . Both aspects affect the increased IHVR to portal flow, and therefore make HSCs interesting targets for the treatment of portal hypertension. Because of their apparent key role, considerable effort has been made to elucidate the regulation that governs contractile force generation in these cells. At present, it is generally assumed that activated HSCs have a smooth muscle cell-like Ca 2ϩ -dependent contraction pattern (2, 5, (22) (23) (24) . This contention is founded on different observations, such as 1) a functional and ultrastructural resemblance to pericytes (22) ; 2) the expression of smooth muscle proteins (like ␣-SMA and myosin II) (5, 26); 3) the expression of L-type voltage-operated Ca 2ϩ channels (2); and 4) the fact that agonists that are known to cause contraction in HSCs are associated with increases in intracellular Ca 2ϩ (22) (23) (24) . Although persuasive, these observations are challenged heretofore by a lack of direct evidence proving that an increase in intracellular Ca 2ϩ indeed mediates force generation and by an apparent contradiction in terminology, as witnessed in the smooth muscle cell-like contraction pattern of a myofibroblastlike activated HSC.
In contrast to previous studies, we applied a three-dimensional stress-relaxed collagen lattice contraction model to study the contractility of HSCs (16, 19, 29, 31 ). The reasons herefore are twofold. First, cell adhesion, analogous to the in vivo situation, occurs three dimensionally to attachment sites made upon protein fibrils rather than two dimensionally along a protein-coated interface (like for contraction studies using confocal Ca 2ϩ imaging or when HSCs are grown on top of polymerized collagen lattices). This model therefore mimics the reciprocal geometric and mechanical relationships with the surrounding matrix that HSCs entertain in vivo (7, 16) . Second, the relevance of stressed gels follows from the observation that in the cirrhotic liver, the injured liver tissue is tethered in a way that cell contraction will inevitably increase stress in the surrounding matrix, resulting in a mechanical feedback that is missing in classically used unrestrained gels ("floating gels") as well as in the classical two-dimensional assay, as mentioned earlier.
Using this in vitro model, we first tested the premise that force generation in HSCs is Ca 2ϩ dependent. We demonstrated that, although Ca 2ϩ /calmodulin-mediated MLCK activity is necessary for HSC contraction, elevation of intracellular Ca 2ϩ was insufficient to cause maximal contraction. These results contrasted with the demonstrated properties of VSMCs, in which gradual elevation of intracellular Ca 2ϩ ultimately led to a similarly efficient contraction as obtained after agonist stimulation, proving the dominance of Ca 2ϩ -dependent pathways in these cells (19, 21, 27, 28) . In cardiac myofibroblasts, quite the reverse phenomenon was observed, since these cells, like other types of myofibroblasts (19) , appeared almost Ca 2ϩ insensitive. These observations clearly refute any comparison for HSCs with smooth muscle cells and myofibroblasts, making terms like "smooth muscle cell like" and "myofibroblast like" inappropriate in this context.
The inability of increased intracellular Ca 2ϩ to promote maximal contraction suggests that activated HSCs have an additional mechanism to Ca 2ϩ /calmodulin-dependent MLCK that is critical in regulating contractility. We therefore tested Ca 2ϩ -independent pathways. Since these pathways are thought to converge in the inactivation of MLCP, resulting in delayed degradation of phosphorylated rMLC and thefore decreased contraction, we first focused on this enzyme (8, 11, 19, 26, 27) . We demonstrated that the phosphatase inhibitor calyculin, in the absence of any agonist, could promote HSC contraction, proving its involvement in the regulation of force generation additive to the Ca 2ϩ -dependent pathway. To further specify its role in this regulation, we examined HSC contraction under Ca 2ϩ -depleted or Ca 2ϩ -containing conditions in the presence or absence of calyculin. These experiments showed that inhibition of MLCP increased the amount of contraction independently of the level of intracellular Ca 2ϩ , suggestive of a phenomenon known as Ca 2ϩ sensitization (21, 27) . In smooth muscle cells, this phenomenon has been extensively described and is mainly attributed to the inhibition of MLCP (21) . Several mechanisms have been identified in these cells to inactivate MLCP, the most important of which are the phosphorylation of the regulatory subunit of MLCP by the Rho/Rho kinase pathway and the inhibition of the catalytic subunit of MLCP mediated by the PKC-dependent pathway (8, 17, 21, 27) . For HSCs, to our knowledge, the concept of Ca 2ϩ sensitization is novel. Reviewing the two aformentioned mechanisms, which are considered to be the main regulating factors in smooth muscle cells in this process, we observed surprising parallels in HSCs. First, we and others (10, 15, 30, 31) , under different conditions, could document a role for the RhoA signaling pathway since preincubation with the Rho kinase inhibitor Y-27632 attenuated contraction and decreased phosphorylation of rMLC, the rate-limiting step in the actomyosin interaction. Furthermore, we also proved that the RhoA signaling pathway acts through MLCP, since preincubation with calyculin, a phosphatase inhibitor, largely counteracted inhibition of contraction by Y-27632. This suggests that Rho kinase, a serine/threonine kinase, phosphorylates MLCP and inhibits phosphatase activity, resulting in delayed degradation of phosphorylated rMLC and thus protracted contraction. Second, we also revealed a role for the PKC-dependent pathway. Stauro- Both Ca 2ϩ -dependent and -independent pathways were shown to be involved in the hyperresponsiveness of the cirrhotic liver to MTX because inhibition of these pathways attenuated the increased intrahepatic vascular resistance (IHVR) with a predominance of Ca 2ϩ -independent pathways, mediated through PKC-and RhoA-mediated signaling cascades. F P Ͻ 0.05 vs. TAA ϩ MTX;
■ P Ͻ 0.05 vs. TAA ϩ W-7; OE P Ͻ 0.05 vs. TAA ϩ Y-27632; E P Ͻ 0.05 vs. normal rat liver ϩ MTX. sporin, a PKC inhibitor, prevented FCS-and methoxaminepromoted contraction and decreased phosphorylation of rMLC. Similarly as for RhoA inhibition, calyculin also almost completely opposed inhibition of contraction by staurosporin, identifying MLCP as the end target of this pathway as well. These results indicate an auxiliary role for PKC to the RhoA pathway as a G protein-coupled effector of Ca 2ϩ sensitization. It should be taken into account that the inhibitors used to block the different pathways are highly specific but not exclusive to their intended target. In addition, a role for MLC phosphorylation-independent regulatory mechanisms is postulated in smooth muscle cells (21) . Our data show that Ca 2ϩ -dependent (MLCK related) and Ca 2ϩ -independent (MLCP related) pathways are important in HSC contraction, but these findings do not exclude the presence or absence of alternative, more discrete pathways. The study of these will require more selective experimental tools and models that are lacking at the moment.
To correlate our in vitro findings to the in vivo situation, we reevaluated these pathways in the in situ perfused liver. We first confirmed the presence of an exaggerated response to methoxamine in the cirrhotic rat liver compared with the normal liver, illustrating the known phenomenon of intrahepatic hyperresponsiveness to vasoconstrictors in the cirrhotic liver (6, 14) . Both Ca 2ϩ -dependent and -independent pathways were shown to be involved in this hyperresponsiveness of the cirrhotic liver since inhibition of these pathways attenuated the increased IHVR. A predominance of the Ca 2ϩ -independent pathways, mediated through PKC-and RhoA-mediated signaling cascades, was demonstrated.
In conclusion, we have shown that both Ca 2ϩ -dependent and Ca 2ϩ -independent pathways are necessary to raise a HSCspecific contraction pattern, which distinguishes them from both typical myofibroblasts and smooth muscle cells. These in vitro findings correlated with the data obtained in the cirrhotic liver where both pathways were involved, with Ca ϩ -independent pathways predominating the picture. A better understanding of the intracellular signal transduction mechanisms leading to HSC contraction and the demonstration of their relevance in the establishment of the increased IHVR in the cirrhotic liver might lead to the identification of novel potential targets for the treatment of portal hypertension. 
